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OBJECTIVES We assessed the incidence, associated clinical parameters and prognostic significance of
complete atrioventricular block (CAVB) complicating acute myocardial infarction (AMI) in
the thrombolytic era and compared them to data from the prethrombolytic era.
BACKGROUND The introduction of new therapeutic modalities to treat AMI, aimed to enhance coronary
reperfusion and to limit myocardial necrosis, was expected to decrease the incidence of CAVB
and to improve prognosis. However, there are only limited data regarding the incidence and
the prognosis of AMI patients with CAVB in the thrombolytic era.
METHODS Data from 3,300 patients from the Israeli Thrombolytic Surveys (prospective, nationwide
surveys of consecutive patients with AMI in all 25 coronary-care units in Israel in 1992 and
1996) were analyzed and compared with data from 5,788 patients included in the SPRINT
(Secondary Prevention Reinfarction Israeli Nifedipine Trial) Registry (1981 to 1983).
RESULTS During the 1990s, the incidence of CAVB was 3.7% compared with 5.3% in the 1980s, p 5
0.0007. In the 1990s, mortality of patients with CAVB was significantly higher than in those
without CAVB at 7 days (odds ratio [OR] 5 4.05 95% CI [confidence interval] 2.34 to 6.82,
30 days OR 5 3.98 [95% CI 2.44 to 6.43] and one-year hazard ratio [HR] 5 2.36, [95% CI
1.68 to 3.30]) and similar in thrombolysis-treated and not-treated patients. Mortality of
patients with CAVB has not changed significantly between the two periods; seven-day OR 5
0.82 (95% CI 0.46 to 1.43); 30-day OR 5 0.78 (95% CI 0.45 to 1.33) and one-year HR 5
0.79 (95% CI 0.54 to 1.56), respectively, in the 1990s as compared to a decade earlier.
CONCLUSIONS The incidence of CAVB complicating AMI is lower in the thrombolytic era than in the
prethrombolytic era. Mortality among patients with CAVB is still high and has not declined
within the last decade. The AMI patients who develop CAVB in the thrombolytic era have
significantly worse prognosis than do patients without CAVB. (J Am Coll Cardiol 1999;34:
1721–8) © 1999 by the American College of Cardiology
Patients with an acute myocardial infarction (AMI) devel-
oping complete atrioventricular block (CAVB) in the pre-
thrombolytic era fared worse during hospitalization than did
patients without this complication, independently of infarct
location (1–7).
How thrombolytic therapy affects the incidence and the
prognosis of CAVB complicating AMI is not well estab-
lished. On the one hand, some reports suggest that the
development of CAVB after thrombolysis might be caused
by successful reperfusion (8). For example, in the TAMI
(Thrombolysis and Angioplasty in Myocardial Infarction)
study (9), CAVB was precipitated by an active component
of reperfusion (thrombolysis, PTCA [percutaneous translu-
minal coronary angioplasty] or reocclusion) in 38% of
patients. On the other hand, other studies hypothesized that
the incidence and mortality from CAVB is expected to be
reduced because thrombolytic therapy decreases infarct size
(10,11). The incidence, in-hospital, and long-term effects of
CAVB complicating AMI have not yet been reported from
a large cohort of consecutive patients in the thrombolytic
era.
Most of the studies, in both eras, compared AMI patients
with and without CAVB. One study only (12) compared
the outcome of patients with CAVB in the pre- and the
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early thrombolytic (1986 to 1988) eras, reporting similar
in-hospital survival associated with CAVB in both periods.
The aim of this study was to analyze the incidence,
short-term and one-year prognosis of patients developing
CAVB in the thrombolytic era and to compare it to data
from the prethrombolytic era, in two large Israeli cohorts of
consecutive patients with AMI.
METHODS
The first cohort of 3,300 unselected, consecutive patients
with AMI was derived from two prospective national
surveys, conducted during January to February 1992 and
1996 and May to July 1996 in all 25 coronary-care units
operating in Israel (the thrombolytic era).
For comparison we used data from a second cohort of
5,788 consecutive patients with a confirmed AMI who were
admitted to 13 coronary-care units operating between Au-
gust 1981 and July 1983, in Israel. The patients were
screened for inclusion in the Secondary Prevention Rein-
farction Israeli Nifedipine Trial (SPRINT) (13) and in-
cluded in the SPRINT Registry.
The diagnostic criteria for AMI (13), infarct size esti-
mated by enzyme levels and infarct location were similar in
both periods. Diagnosis of AMI was based on the presence
of any two of the following criteria: typical chest pain lasting
at least 30 min; new electrocardiographic (ECG) changes
(Q/QS and/or ST-segment and T-wave changes), or rise of
at least two of the three serum cardiac enzymes (creatine
kinase, aspartate aminotransferase, and lactate dehydroge-
nase) to more than 1.5 times the upper limit, or concomi-
tant rise of creatine kinase (CK) and MB isoenzyme. The
AMI location was determined by the Minnesota Code (14)
as follows: anterior (V1 through V5), inferior (L2, L3 or
aVF), lateral (L1, aVL or V6) and undetermined if complete
left bundle brunch block concealed the site of infarction.
The thrombolytic surveys and the SPRINT Registry files
included demographic and medical data of patients from the
index hospitalization, medical history, in-hospital course
and complications. Pharmacological therapy and interven-
tional procedures performed during the index hospitaliza-
tion were recorded for both periods. During the survey
period in 1992 and 1996, we employed a conservative
strategy of “watchful waiting” where coronary angiography
followed by mechanical reperfusion was used only for
patients with spontaneous or provocative ischemia (15).
Complete heart block was defined as a third-degree
atrioventricular block when no atrial activity was conducted
to the ventricles (16) and a ventricular rate of #50 beats/min.
All medical summary reports of the patients with the
diagnosis of CAVB were reviewed. Fifteen reports were not
available for review (12/356; 3.4%) from the prethrombo-
lytic era and 3/140 reports (2.1%) from the 1990s), and
these patients were excluded.
To avoid inclusion of patients with CAVB in whom such
an event was not part of the “natural history” of AMI
complicated by CAVB, patients in whom CAVB occurred
as a terminal event were also excluded. Therefore, exclusion
criteria were 1) CAVB developing as a terminal rhythm in
the setting of cardiogenic shock or pump failure developing
during hospitalization in the coronary care unit (CCU).
Patients who presented with CAVB and cardiogenic shock
on admission were included; and 2) transient CAVB occur-
ring during mechanical revascularization. Fifty-four such
patients (39/356 [10.9%] in the 1980s and 15/140 [10.7%]
in the 1990s) were therefore excluded.
Mortality rates at seven days, 30 days and one year in
both study periods were assessed from medical charts and by
matching the identification numbers of the patients with the
Israeli National Population Register.
Statistical analysis. Statistical analysis was performed us-
ing SAS software. The chi-square test and t test were used
to determine the significance of the differences between
proportions and means, respectively. Results of continuous
variables are reported as mean 6 SD. A p value # 0.05 was
considered statistically significant.
To compare mortality in the two periods (1992 to 1996
vs. 1981 to 1983), the adjusted OR with 95% CI for seven-
and 30-day mortality was calculated using the LOGISTIC
procedure (17). Multivariate analysis of one-year and 30-
day to one-year mortalities was performed using the Cox
proportional hazard model (PHREG procedure) (18). Ad-
justment was made for age, gender, history of diabetes
mellitus, hypertension, angina, previous AMI, congestive
heart failure on admission, and anterior infarct location. A
similar method of analysis was used to compare mortality in
patients with and without CAVB in 1992 and 1996.
Logistic regression analysis was used to determine signifi-
cant predictors of CAVB in the thrombolytic era.
Survival curves were constructed using the Kaplan-Meier
method. The significance of the differences between the
survival curves was assessed by the log-rank test (SAS
LIFETEST Procedure).
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AMI 5 acute myocardial infarction
CAVB 5 complete atrioventricular block
CCU 5 coronary care unit
CI 5 confidence interval
CK 5 creatine kinase
HR 5 hazard ratio
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary
angioplasty
RR 5 relative risk
SPRINT 5 Secondary Prevention Reinfarction Israeli
Nifedipine Trial
TAMI 5 Thrombolysis and Angioplasty in
Myocardial Infarction
TIMI 5 Thrombolysis in Myocardial Infarction trial
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RESULTS
Patients in the thrombolytic era: CAVB versus non-
CAVB. The frequency of CAVB in the thrombolytic era
was 3.7% (122/3,300). Patients who developed CAVB in
1992 and 1996 were older (66 6 12 vs. 63 6 13 years, p 5
0.005), included more women (40% vs. 25%, p , 0.001)
and, as expected, had a lower incidence of anterior infarct
location (11% vs. 45%, p , 0.0001) and non-Q-wave AMI
(10% vs. 23%, p , 0.002) than did those without CAVB.
A multivariate analysis performed to identify independent
risk factors for the occurrence of CAVB revealed that
female gender, treatment with thrombolysis and a Killip
class $2 at presentation were associated with an increased
risk for the development of CAVB (Table 1). Anterior
location of infarct and a history of angina pectoris were
inversely associated with CAVB.
In the thrombolytic era, seven-day (21% vs. 6%), 30-day
(29% vs. 10%), and one-year cumulative crude mortality
rates (35% vs. 15%) (p , 0.00001 for each) were higher
among patients who experienced CAVB than in those who
did not (Fig. 1). These differences in prognosis persisted
also after multivariate adjustment (Table 2); 7-day OR 5
4.05 (95% CI 2.34 to 6.82), 30-day OR 5 3.98 (95% CI
2.44 to 6.43) and one-year HR 5 2.36 (95% CI 1.68 to
3.30). Therefore, CAVB emerged as an independent pre-
dictor of mortality in the thrombolytic period.
One-year mortality among 30-day survivors was similar
in those with and without CAVB (HR 5 0.93, 95% CI 0.41
to 2.14).
Patients with CAVB in the thrombolytic era: Thrombol-
ysis versus non-thrombolysis. During the 1992 and 1996
surveys, 1,567/3,300 patients (47.5%) were treated with
thrombolytic agents (Table 3). A trend toward a higher
crude incidence of CAVB was observed in patients treated
(68/1,567, 4.3%) versus not treated with thrombolysis
(54/1,733, 3.1%; p 5 0.07). To exclude selection bias of
patients with CAVB to either therapy, the causes for
excluding patients from thrombolysis were analyzed. Late
arrival (suggesting underestimation of the incidence of early
occurrence of transient CAVB) and previous treatment with
beta-blockers (thus increasing the likelihood for developing
CAVB) (12), which might be possible causes for excluding
patients from thrombolysis, were equally distributed in
those who developed CAVB and those who did not. Other
reasons for ineligibility for thrombolysis (i.e., bleeding
tendency, neoplastic disease, a recent cerebrovascular event)
were similarly distributed between the two groups as well.
Patients who were treated with thrombolytic therapy and
developed CAVB were younger (62 vs. 71 years, p 5
0.0001) and had a lower incidence of a previous myocardial
infarction, cerebrovascular accident and diabetes mellitus
and a higher incidence of smoking history than did coun-
terparts who did not undergo thrombolysis, reflecting the
differences in baseline characteristics between all patients
being treated with thrombolysis and those not being
treated.
A multivariate analysis performed to identify independent
risk factors for the occurrence of CAVB revealed that
thrombolytic therapy was independently associated with a
twofold increased risk for the development of CAVB
(Table 1).
Thirty-day mortality among inferior AMI patients with
CAVB was significantly higher than in counterparts with-
out CAVB, irrespective of whether they received (CAVB vs.
no-CAVB: 22% vs. 5%, respectively, p , 0.001) or did not
Table 1. Parameters Predicting Development of CAVB in the
Thrombolytic Era
Premature
OR of
CAVB 95% CI
Age (10 yr increment) 1.16 0.98–1.38
Female gender 1.72 1.14–2.59
Anterior infarction 0.11 0.06–0.20
Killip class $2 2.88 1.88–4.38
Thrombolytic therapy 2.06 1.38–3.08
Past angina 0.61 0.40–0.91
Stepwise from age, gender, anterior AMI, previous AMI, Killip $2, thrombolytic
therapy, diabetes mellitus, hypertension, past angina.
CAVB 5 complete atrioventricular block; CI 5 confidence intervals; OR 5 odds
ratio.
Figure 1. One-year survival curves for patients with and without
CAVB complicating AMI in the thrombolytic surveys (p by the
log-rank test 5 0.0001).
Table 2. Odds Ratios and Hazard Ratios of Mortality of
Patients With CAVB Complicating AMI
OR*/HR†
(95% CI)
1992–1996 vs.
1981–1983
1992–1996 CAVB vs.
non-CAVB
7-day 0.82 (0.46–1.43) 4.05 (2.34–6.82)
30-day 0.78 (0.45–1.33) 3.98 (2.44–6.43)
30-day to 1-year 0.49 (0.18–1.31) 0.93 (0.41–2.14)
1-year cumulative 0.79 (0.54–1.56) 2.36 (1.68–3.30)
*Odds ratio for 7- and 30-day or †hazard ratio for 30-day to one-year and one-year
cumulative mortality. Adjusted for age, gender, diabetes mellitus, hypertension,
angina, previous infarction, heart failure on admission and anterior infarct location.
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receive thrombolytic therapy (CAVB vs. no-CAVB: 35%
vs. 8%, respectively, p , 0.001). Similar findings were
observed in patients with anterior AMI who were not
treated with thrombolysis: mortality among patients with
CAVB was significantly higher than in counterparts with-
out CAVB: 67% vs. 16%, respectively, p 5 0.007. Thirty-
day mortality among anterior AMI patients who were
treated with thrombolysis did not differ between patients
with CAVB and counterparts without CAVB (14% vs. 9%,
respectively, p 5 NS). However, the number of patients
with CAVB complicating anterior AMI was small—13
patients—so conclusions from such numbers should be
interpreted with caution.
Seven-day crude mortality among patients with CAVB
who were treated by thrombolytic therapy in 1992 and 1996
was similar to that of counterparts not treated with throm-
bolysis, whereas late mortality (30 day and one year) was
lower among thrombolysis-treated patients. (Table 4 and
Fig. 2). However, after adjustment, no difference in mor-
tality was observed between the two groups of patients with
CAVB: the 7- and 30-day OR were 0.82 (95% CI 0.30 to
2.26) and 0.49 (95% CI 0.20 to 1.17), respectively, and the
one-year HR was 0.87 (95% CI 0.41 to 1.84).
Patients with CAVB: 1992 and 1996 versus 1981–1983.
The frequency of CAVB complicating AMI decreased
significantly in the thrombolytic era as compared with a
decade earlier (3.7% vs. 5.3%, p 5 0.0007) (Table 3).
Baseline characteristics of patients with CAVB were similar
in both periods, except for a higher incidence of a history of
angina and a lower incidence of diabetes mellitus among
patients included in the 1981 to 1983 cohort (Table 3). The
incidence of CAVB was even higher when comparing the
prethrombolytic cohort with the group of patients in the
Table 3. Baseline Characteristics of Patients With CAVB Complicating AMI
%
SPRINT
1981–1983
(n 5 5,788)
p Value*
Thrombolytic Surveys 1992 and 1996 (n 5 3,330)
All CAVB
(n 5 305)
All CAVB
(n 5 122)
Thrombolysis
(n 5 68) p Value†
No Thrombolysis
(n 5 54)
CAVB 5.3 0.0007 3.7 4.3 0.07 (NS) 3.1
Age (yrs) (mean 6 SD) 66 6 10 NS 66 6 12 62 6 12 0.0001 71 6 12
Male 68 NS 60 65 NS 55
History
MI 24 NS 20 10 0.004 32
Angina pectoris 49 0.001 31 34 NS 28
Hypertension 47 NS 41 37 NS 46
Diabetes mellitus 19 0.04 28 21 0.04 37
Cerebrovascular accident 5 NS 4 0 0.01 9
Current smokers 28 NS 34 47 0.001 19
Infarct location 0.002 NS
Anterior 27 11 12 11
Inferior/Posterior 73 88 88 88
Lateral 0 1 0 1
Undetermined 0 0.4 0 0
Non-Q-wave MI 4 0.02 10 7 NS 16
*Comparing patients with CAVB in 1981–83 and 1992 and 1996 cohort. †Comparing thrombolyzed and nonthrombolyzed patients with CAVB in 1992–1996.
CAVB5 complete atrioventricular block; MI 5 myocardial infarction; NS 5 nonsignificant.
Table 4. Crude Mortality Rates of Patients With CAVB Complicating AMI
SPRINT
1981–1983
(n 5 5,788)
p Value*
Thrombolytic Surveys
1992 and 1996 (n 5 3,300)
All CAVB
(n 5 305)
All CAVB
(n 5 122)
Thrombolysis
(n 5 68) p Value†
No Thrombolysis
(n 5 54)
Mortality (%)
7 day 31 0.04 21 16 NS 28
30 day 42 0.01 29 21 0.02 40
30 day to 1 year 14 NS 7 6 NS 10
1-year cumulative 50 0.005 35 26 0.01 48
*By univariate analysis between the 1981–1983 and 1992 and 1996 cohorts. †By univariate analysis between thrombolyzed and nonthrombolyzed patients.
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1990s not treated with thrombolysis (5.3% vs. 3.1%, p 5
0.0001), despite worse clinical predictors of mortality in the
latter group.
Infarct location among patients who developed CAVB
differed between the two cohorts; anterior location was less
prevalent and inferior/posterior location was more prevalent
in the thrombolytic era as compared with the prethrombo-
lytic era (p 5 0.002) (Table 3).
In addition, no significant reduction in one-year mortality
was observed in the thrombolytic era among patients with
both anterior (54% vs. 75%, p 5 NS) and inferior (32% vs.
41%, p 5 NS) sites of infarction, compared with the
prethrombolytic era.
Timing of the occurrence of CAVB was evaluated. This
complication was observed on hospital admission in 55%
and in 73% of patients with CAVB (for whom timing was
reported), in the 1980s and 1990s, respectively. Within the
first 48 h, an additional 34% and 21% of patients in the
prethrombolytic and the thrombolytic eras, respectively,
developed CAVB. Thus, 87% and 94% of CAVBs occurred
early in the course of AMI.
Seven-, 30-day and one-year crude mortality rates in
patients with CAVB were relatively high but lower in the
thrombolytic era in comparison to the prethrombolytic era
(21%, 29% and 35% vs. 31%, 42% and 50%, respectively)
(Table 4 and Fig. 2). However, following multivariate
analysis, the adjusted risk of mortality was similar to that in
the previous decade (Table 2); 7-day OR 5 0.82 (95% CI
0.46 to 1.43); 30-day OR 5 0.78 (95% CI 0.45 to 1.33) and
one-year HR 5 0.79 (95% CI 0.54 to 1.56).
Moreover, a significant reduction in 30-day mortality was
observed among men with CAVB in the thrombolytic era in
comparison to the prethrombolytic era (24% vs. 37%, p ,
0.04). No significant reduction in mortality was observed in
patients with first or recurrent AMI, anterior or inferior
sites of infarction in both periods.
The one-year outcome of 30-day survivors with CAVB
during hospitalization in 1992 and 1996, was not signifi-
cantly different from that of patients in 1981 to 1983: 7%
versus 14% (p 5 NS), HR 5 0.49, 95% CI 0.18 to 1.31).
DISCUSSION
To our knowledge, this is the first population-based, mul-
ticenter, nationwide study of CAVB complicating AMI in
the thrombolytic era.
The present study shows a significant decrease in the
occurrence of CAVB after AMI in the thrombolytic (3.7%)
as compared to the prethrombolytic era (5.3%). Despite this
improvement, adjusted mortality among patients with
CAVB has not changed within the last decade. Mortality of
patients with CAVB remained higher than that of patients
without CAVB. Similar to observations from the prethrom-
bolytic era, the occurrence of CAVB during AMI in the
1990s had no impact on one-year mortality among 30-day
survivors.
Incidence. The incidence of CAVB in the thrombolytic
era was reduced compared to the prethrombolytic era in
accordance with most (3,5,19,20) but not all (12) previous
studies. Interestingly, the incidence of CAVB among our
patients with inferior myocardial infarction (6.0%) is lower
than that in the TAMI (Thrombolysis and Angioplasty in
Myocardial Infarction) (13%) and TIMI (Thrombolysis in
Myocardial Infarction) (12%) studies (9,21). This could be
explained by the differences between the populations: our
study is a nationwide study that includes the entire AMI
population, whereas the TIMI and TAMI studies include a
highly selected population referred to tertiary hospitals for
thrombolysis. In addition, all patients in the TIMI and
TAMI trials received thrombolysis; in our study, only 47%
of patients were treated with lytic therapy.
The observed reduced incidence of CAVB among pa-
tients with both anterior and inferior infarction in 1992 and
1996 versus the previous decade may be related to enhanced
coronary perfusion and myocardial revascularization in the
thrombolytic era, thus limiting infarct size and preserving
ventricular function (10,11). The reduced incidence of
CAVB, also observed among nonthrombolysed patients,
probably reflects an overall change in management of all
AMI patients treated today, as has recently been shown,
both in Europe (22) and North America (23,24).
Studies from the prethrombolytic era report the presence
of CAVB in up to 55% of patients developing this compli-
cation, upon hospital admission and in up to 75% within
24 h (2,3,19,20), similar to the TIMI (21) and TAMI (9)
trials in which CAVB was with this event present in 53%
and 54% of cases with this event, respectively, upon admis-
sion and in 96% within 72 h. These figures are in accor-
dance with the data reported in our study: 87% of cases in
the prethrombolytic and 94% in the thrombolytic eras,
respectively, of all CAVB cases appear within 48 h after
admission.
Figure 2. One-year survival curves for patients with CAVB
complicating AMI in the prethrombolytic and thrombolytic eras.
TTx (1) 5 thrombolytic therapy; TTx (2) 5 no thrombolytic
therapy. When comparing the thrombolysed groups in 1992 and
1996 with the 1981 to 1983 cohort, p 5 0.006.
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Pathogenesis. The CAVB complicating anterior AMI is
usually within the HIS-Purkinje system and is related to
interruption of septal perfusion accompanied by extensive
myocardial damage and significant left ventricular dysfunc-
tion (3,4). In inferior AMI, CAVB usually involves the
supra-Hissian atrioventricular junction (25) due to hypoper-
fusion of the atrioventricular nodal artery.
The reperfusion of the infarct-related artery should con-
ceivably reduce the incidence of CAVB in both anterior and
inferior infarctions. Surprisingly, we found that the inci-
dence of CAVB was not reduced by thrombolytic therapy
and the additional procedures aimed at infarct and ischemic
area reduction. Furthermore, thrombolytic therapy was
found to be an independent risk factor for developing
CAVB. The reason for this interesting finding is unknown.
It might be due to association—patients with higher ST-
segment elevation are more likely to have a larger AMI,
therefore more likely to receive thrombolysis. Such patients
might be more prone to develop CAVB. One possible
mechanism may be vagally mediated CAVB, which has
been suggested as a sign of successful reperfusion (8). This
results from restoration of flow that facilitates leukocyte
migration to the infarcted area, stimulating vagal innerva-
tion within the infarcted myocardium (26). Additionally,
CAVB may occur as a consequence of reocclusion following
successful reperfusion (occurring in 14% of CAVB patients
in the TAMI trial) (9). Finally, reperfusion injury may
further hamper the conduction system; reperfusion was a
precipitating event in 10% of CAVB patients in the TAMI
trial (9). In the latter study, CAVB was associated with “an
active component of reperfusion” in almost 40% of patients.
In our study, a history of angina pectoris was negatively
associated with the development of CAVB, in accordance
with a recent study suggesting that absence of preinfarction
angina predicted the development of CAVB (27). Prein-
farction angina is accompanied by a smaller infarct size,
preservation of left ventricular function (preconditioning)
and a higher and more rapid patency of the infarct-related
artery (28,29), therefore reducing the occurrence of peri-
atrioventricular nodal ischemia.
Mortality. In the present study, patients who developed
CAVB after AMI showed no significant reduction of the
adjusted short-term and one-year mortality, compared to
the prethrombolytic era.
Patients with CAVB during AMI have an increased
in-hospital mortality and fare worse than do counterparts
with no CAVB (3,4,6). Their prognosis is particularly poor
during hospitalization (2,7,9,20), in both the prethrombo-
lytic (7,30) and the thrombolytic eras (9,31). Similar obser-
vations were made in the present study; the seven- and
30-day mortality was about four times higher and the
one-year mortality was twice as high among patients with
CAVB than among counterparts who did not develop this
complication.
Previous studies have shown that the immediate poorer
prognosis of AMI patients with CAVB results from larger
infarctions (32) with a correlation between infarct size and
the occurrence of CAVB in both anterior and inferior
infarctions (33). Apparently, CAVB is not responsible for
the increased mortality (20), but rather is a marker for an
increased infarct size. In addition, CAVB was indepen-
dently associated with increased in-hospital mortality, both
in the previous decade (7) and in the 1990s (9). Our
previous study (7) reported a mortality rate four times
higher among anterior AMI patients with CAVB than
among counterparts without CAVB. We (20) and others
(2,5,9) also reported a higher mortality among inferior AMI
patients with CAVB than among those with no CAVB
(RR 5 2.0).
The frequent resolution of CAVB in AMI survivors is
related to spontaneous (34) or medical (35) reperfusion,
resulting in disappearance of atrioventricular nodal isch-
emia. Mortality among 30-day survivors in the 1990s was
not affected by the occurrence of CAVB as we (7,20) and
others (12,36,37) previously reported.
Mortality among inferior AMI patients with CAVB was
similar among those treated and not treated with throm-
bolysis, despite better baseline characteristics in the former.
This could be attributed to the deleterious effect of the
occurrence of CAVB on prognosis, which counterbalances
the theoretical benefit that could have been achieved with
thrombolysis. The presence of CAVB could possibly
reduce the benefit of thrombolytic therapy because of the
associated bradycardia and hypotension. This hypothesis is
supported by a higher incidence of TIMI-0 flow in the
atrioventricular-block group (31).
Survival in nonthrombolyzed patients with CAVB in
1992 to 1996 was not better than in 1981 to 1983. This may
reflect the effects of two opposing factors: nonthrombolysed
patients with CAVB today have worse baseline character-
istics in comparison to CAVB patients a decade ago (Table
3); however, improvement in drug therapy (i.e., increased
use of aspirin, beta-blockers and ACE [angiotensin-
converting enzyme] inhibitors) contributes to reduced cur-
rent mortality (22–24).
Study limitations. The SPRINT Registry and the 1992 to
1996 cohort were derived from prospective nationwide
surveys, which were not designed to address patients with
CAVB specifically. Thus, no data on duration of CAVB or
its relation to initiation of thrombolytic therapy were
available.
The use of historical controls is a limitation because of
the changes in therapy that occurred during the last decade,
such as ACE inhibitors, aspirin, beta-blockers, and me-
chanical revascularization. However, although such inter-
ventions were expected to reduce mortality in the 1990s, this
has not changed significantly between the two periods.
Conclusions. The incidence of CAVB in the general AMI
population declined in the thrombolytic era compared to the
previous decade. However, CAVB is still accompanied by a
1726 Harpaz et al. JACC Vol. 34, No. 6, 1999
Complete Atrioventricular Block in the Thrombolytic Era November 15, 1999:1721–8
poor early prognosis, whereas the long-term outcome of
hospital survivors is similar to patients who did not experi-
ence CAVB during hospitalization. A more aggressive
therapeutic approach aimed to reduce early mortality seems
warranted in these patients.
APPENDIX 1
SPRINT Study Group: Henry N. Neufeld, MD (deceased);
Jacob Agmon, MD; Solomon Behar, MD; Uri Goldbourt,
PhD; Henrietta Reicher-Reiss, MD; Edward Abinader,
MD; Jacob Barzilay, MD; Yaacov Friedman, MD; Nissim
Kauli, MD; Yehezkiel Kishon, MD; Abraham Palant, MD;
Benyamin Peled, MD; Leonardo Reisin, MD; Egon Riss,
MD (deceased); Zwi Schlesinger, MD; Izhar Zahavi, MD;
Monty Zion, MD.
Participating Centers in Israel, Principal Investigators and
Physicians: Assaf Harofeh Hospital, Zerifin: Zwi Schlesinger,
MD, Principal Investigator; Moshe Algom, MD. Barzilai
Medical Center, Ashkelon: Leonardo Reisin, MD, Principal
Investigator; Newton Yalom, MD. Beilinson Medical Center,
Petach Tikvah: Yaacov Friedman, MD, Principal Investiga-
tor. Carmel Hospital and Medical “Lin,” Haifa: Abraham
Palant, MD, Principal Investigator; Ephraim Mayer, MD.
Central Emek Hospital, Afula: Jacob Barzilay, MD, Principal
Investigator; Lev Bloch, MD. Hasharon Hospital, Petach
Tikvah: Izhar Zahavi, MD, Principal Investigator; Men-
achem Katz, MD. Hillel Yaffe Hospital, Hadera: Benyamin
Peled, MD, Principal Investigator; Zakki Abu-Moukh,
MD. Kaplan Hospital, Rehovot: Nissim Kauli, MD, Princi-
pal Investigator; Emanuel Liebman, MD. Rambam Medical
Center, Haifa: Egon Riss, MD, MSc, Principal Investigator
(deceased); Jamil Hir, MD. Bnei Zion Center, Haifa: Ed-
ward Abinader, MD, Principal Investigator; Ehud Gold-
hammer, MD, Acting Principal Investigator; Salim Maal-
ouf, MD. Shaare Zedek Medical Center, Jerusalem: Monty
Zion, MD, Principal Investigator; David Rosenmann, MD;
Jonathan Balkin, MD. Sheba Medical Center, Tel Hashomer:
Henrietta Reicher-Reiss, MD; Principal Investigator. Wolf-
son Medical Center, Holon: Yehezkiel Kishon, MD, Principal
Investigator; Ron Narinsky, MD (deceased).
Coordinating Center: Sheba Medical Center, Tel Hashomer:
Solomon Behar, MD; Uri Goldbourt, PhD; Henrietta
Reicher-Reiss, MD; Lori Mandelzweig, MPH.
APPENDIX 2
Participating Centers, Directors of the Cardiac Departments
and Responsible Physicians of the Israeli Thrombolytic Sur-
veys: Assaf Harofeh Hospital, Zerifin: Zwi Schlesinger, MD,
Hady Faibel, MD. Barzilai Medical Center, Ashkelon: Leo-
nardo Reisin, MD, Jamal Jafari, MD. Bnei-Zion Medical
Center, Haifa: Edward Abinader, MD, Ehud Goldhammer,
MD. Bikur Cholim Medical Center: Shlomo Stern, MD,
Shmuel Gottlieb, MD, Andre Keren, MD. Carmel Medical
Center, Haifa: Basil S. Lewis, MD, Nabil Mahul, MD,
David Hallon, MD, Moshe Flugelman, MD. Carmel Med-
ical Center and Lin Medical Clinic, Haifa: Avraham Palant,
MD, Chen Shapira, MD. Central Emek Hospital, Afula:
Tiberio Rosenfeld, MD, Nahum A. Friedberg, MD. Ha-
dassah, Ein-Kerem Medical Center, Jerusalem: Mervyn S.
Gotsman, MD, Yonatan Hasin, MD. Hadassah, Mount-
Scopus Medical Center, Jerusalem: Teddy A. Weiss, MD,
Shimon Rosenheck, MD. Hillel Yaffe Medical Center,
Hadera: Benyamin Peled, MD, Msc, Fatchy Daka, MD,
Magdalah Rashmi, MD. Josephtal Medical Center, Eilat:
Alen Gelvan, MD. Kaplan Medical Center, Rehovot: Avra-
ham Caspi, MD, Oskar H. Kracoff, MD, Michael Oet-
tinger, MD. Laniado Medical Center, Netanya: Eddi
Barasch, MD. Poriah Medical Center, Tiberius: Leonid
Rudnik, MD, Shai Reifler, MD. Rabin Medical Center:
Beilinson Campus, Petach Tikvah: Samuel Sclarovsky, MD,
Eldad Rehavia, MD, Boris Strasberg, MD. Golda (Hasha-
ron) Campus, Petach Tikvah: Izhar Zahavi, MD, Menachem
Kanetti, MD. Rambam Medical Center, Haifa: Walter
Markiewicz, MD, Boaz Benari, MD, Haim Hammerman,
MD. Rebecca Ziv Medical Center, Safed: Alon Marmour,
MD, David Blondheim, MD. Shaare Zedek Medical Center,
Jerusalem: Dan Tzivoni, MD, Mark Klutstein, MD,
Jonathan Balkin, MD. Sheba Medical Center, Tel Hashomer:
Elieser Kaplinsky, MD, Hanoch Hod, MD. Sapir Medical
Center, Meir Hospital, Kfar Saba: Daniel David, MD, Hana
Pauzner, MD. Sorasky Medical Center, Ichilov Hospital, Tel
Aviv: Shlomo Laniado, MD, Arie Roth, MD. Soroka
Medical Center, Be’er Sheba: Natalio Kristal, MD, Amos
Katz, MD, Alexander Battler, MD, Arie Gilutz, MD.
Western Galilee Medical Center, Naharia: Nathan Roguin,
MD. Wolfson Medical Center, Holon: Yehezkiel Kishon,
MD, Ron Narinsky, MD (deceased), Michael Kriwiski,
MD.
Coordinating Center of the Israeli National Thrombo-
lytic Survey, Neufeld Cardiac Research Institute, Sheba Med-
ical Center, Tel Hashomer, Israel: Solomon Behar, MD
(director); and Shmuel Gottlieb, MD.
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